Actinomycin Export Market Intelligence: India's 184 Suppliers Shipping to 97 Countries — TransData Nexus 2026

Q: Who are the top actinomycin exporters from India?

The top actinomycin exporters from India are: 1. EUGIA PHARMA SPECIALITIES LIMITED — $1.8M (61.4% market share); 2. MYLAN LABORATORIES LIMITED — $348.8K (11.9% market share); 3. IKRIS PHARMA NETWORK PRIVATE LIMITED — $108.1K (3.7% market share); 4. CELON LABORATORIES PRIVATE LIMITED — $67.3K (2.3% market share); 5. GNH INDIA PHARMACEUTICALS LIMITED — $53.4K (1.8% market share). Together they account for 81.1% of India's total actinomycin export value.

Q: What is the total export value of actinomycin from India?

The total export value of actinomycin from India is $2.9M USD, recorded across 933 shipment transactions from 184 active exporters to 97 destination countries. The average shipment value is $3.1K.

Q: Which countries import actinomycin from India?

India exports actinomycin to 97 countries worldwide. The top importing countries are: UNITED STATES (73.5% share, $2.2M), BRAZIL (8.4% share, $245.8K), UGANDA (1.3% share, $37.6K), ETHIOPIA (1.2% share, $36.0K), UNITED ARAB EMIRATES (1.1% share, $31.3K). These five markets account for 85.5% of total export value.

Q: What is the HS code for actinomycin exports from India?

The primary HS code for actinomycin exports from India is 30049046. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of actinomycin exports from India?

The average unit price for actinomycin exports from India is $14.44 USD per unit, with prices ranging from $0.13 to $501.53 depending on formulation, packaging, and order volume. The total market is valued at $2.9M across 933 shipments.

Q: Which ports handle actinomycin exports from India?

The primary ports for actinomycin exports from India are SAHAR AIR (32.6% of shipments), SAHAR AIR CARGO ACC (INBOM4) (19.7% of shipments), DELHI AIR (11.6% of shipments), Bombay Air (8.8% of shipments), DELHI AIR CARGO ACC (INDEL4) (6.6% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of actinomycin?

India is one of the world's leading exporters of actinomycin due to its large base of 184 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports actinomycin to 97 countries, demonstrating 50% global market coverage.

Q: What certifications do Indian actinomycin exporters need?

Indian actinomycin exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import actinomycin from India?

There are 351 registered buyers importing actinomycin from India, spread across 97 countries. The repeat buyer rate is 28.8%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top actinomycin supplier from India?

EUGIA PHARMA SPECIALITIES LIMITED is the leading actinomycin exporter from India with a market share of 61.4% and total export value of $1.8M across 5 shipments. The top 5 suppliers together control 81.1% of total export value.

Suresh Sormare

Actinomycin

India Pharmaceutical Trade Intelligence

$2.9M184 Suppliers97 CountriesHS 30049046

ExportsIndia → UNITED STATES73.5%India → BRAZIL8.4%

ImportsUNITED STATES → India$114

#1 Supplier: EUGIA PHARMA #1 Buyer: EUGIA US

Actinomycin Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Actinomycin to the World

Between 2022 and 2026, India exported $2.9M worth of actinomycin across 933 verified shipments to 97 countries — covering 50% of world markets in the Advanced Oncology segment. The largest destination is UNITED STATES (73.5%). EUGIA PHARMA SPECIALITIES LIMITED leads with a 61.4% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Actinomycin export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Actinomycin export data snapshot — $2.9M · 184 exporters · 97 countriesTransData Nexus · Indian Customs Data

Top Actinomycin Exporters from India

184 active exporters · Ranked by export value

View all 184 →

Top Actinomycin Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	EUGIA PHARMA SPECIALITIES LIMITED	$1.8M	5	1	61.4%
2	MYLAN LABORATORIES LIMITED

Top Countries Importing Actinomycin from India

97 destination markets · Ranked by import value

All 97 countries →

Top Countries Importing Actinomycin from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	UNITED STATES	$2.2M	73.5%
2	BRAZIL	$245.8K	8.4%
3	UGANDA	$37.6K	1.3%
4	ETHIOPIA	$36.0K	1.2%
5	UNITED ARAB EMIRATES	$31.3K	1.1%
6	MOROCCO	$31.3K	1.1%
7	SRI LANKA	$24.5K	0.8%
8	RWANDA	$23.5K	0.8%
9	IRAQ	$21.1K	0.7%
10	KENYA	$14.6K	0.5%

UNITED STATES is India's largest actinomycin export destination, absorbing 73.5% of total exports worth $2.2M. The top 5 importing countries — UNITED STATES, BRAZIL, UGANDA, ETHIOPIA, UNITED ARAB EMIRATES — together account for 85.5% of India's total actinomycin export value. The remaining 92 destination countries collectively receive the other 14.5%, indicating a broadly diversified export footprint across multiple regions.

Who Supplies Actinomycin to India?

1 origin countries · Total import value: $114

India imports actinomycin from 1 countries with a combined import value of $114. The largest supplier is UNITED STATES ($114, 2 shipments), followed by . All values are from Indian Customs (DGFT) import records.

Countries Supplying Actinomycin to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	UNITED STATES	$114	2	100.0%

UNITED STATES is the largest supplier of actinomycin to India, accounting for 100.0% of total import value. Click any country to see detailed supplier and buyer data for that import corridor.

Actinomycin — Export Intelligence Video

Visual overview of India's actinomycin import and export market — top suppliers, destinations, pricing, and trade routes

This video covers India's actinomycin pharmaceutical import and export market — $2.9M in total trade, 184 verified manufacturers, and 97 destination countries. Data sourced from Indian Customs (DGFT) shipment records.

Regulatory Landscape — Actinomycin

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

Actinomycin, known in the United States as dactinomycin, is an antineoplastic antibiotic used primarily in the treatment of various cancers. According to the FDA's Orange Book, there are several approved Abbreviated New Drug Applications (ANDAs) for dactinomycin, indicating the presence of generic versions in the market. The most recent approval was granted in June 2025. The regulatory pathway for dactinomycin involves submission of an ANDA, demonstrating bioequivalence to the reference listed drug, without the need for extensive clinical trials.

Our proprietary trade data indicates that India exported actinomycin worth $2.9 million USD between 2022 and 2026, with 73.5% of these exports destined for the United States. This substantial export volume underscores the significance of the U.S. market for Indian manufacturers. Notably, EUGIA PHARMA SPECIALITIES LIMITED accounted for 61.4% of these exports, highlighting their dominant position in supplying actinomycin to the U.S.

2EU & UK Regulatory Framework

In the European Union, the European Medicines Agency (EMA) oversees the approval and regulation of medicinal products. Dactinomycin is authorized for use in the EU, with marketing authorizations granted to various pharmaceutical companies. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) continues to regulate dactinomycin post-Brexit, maintaining alignment with EU standards. Manufacturers exporting to these regions must comply with EU Good Manufacturing Practice (GMP) requirements, ensuring product quality and safety.

3WHO Essential Medicines & Global Standards

Dactinomycin is listed in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, signifying its importance in treating priority health conditions globally. Inclusion in this list guides countries in developing their national essential medicines lists. Additionally, dactinomycin is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality specifications across different regions.

4India Regulatory Classification

In India, dactinomycin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for dactinomycin, allowing market-driven pricing. For export purposes, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and monitoring of pharmaceutical exports.

5Patent & Exclusivity Status

The primary patents for dactinomycin have expired, leading to the availability of generic versions and increased competition in the market. This has facilitated the entry of multiple manufacturers, including Indian exporters, into international markets.

6Recent Industry Developments

In August 2025, the NPPA announced a review of pricing policies for essential medicines, potentially impacting the pricing structure for drugs like dactinomycin. In October 2025, the EMA updated its guidelines on GMP compliance, emphasizing stricter quality control measures for oncology drugs, including dactinomycin. In December 2025, the WHO released the 24th edition of its Model List of Essential Medicines, reaffirming the inclusion of dactinomycin, which may influence national policies on its procurement and use.

These developments reflect the dynamic regulatory environment affecting the production, pricing, and distribution of dactinomycin, with implications for manufacturers and exporters.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Actinomycin

Retail & reference prices across 9 markets vs. India FOB export price of $14.44/unit

Global Price Benchmark for Actinomycin across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$50	USD	According to the FDA's Orange Book, Actinomycin D is an approved chemotherapeutic agent.
United Kingdom	Approximately $55	GBP	As per the NHS Drug Tariff, Actinomycin D is listed for use in oncology treatments.
Germany	Approximately $50	EUR	The European Medicines Agency (EMA) includes Actinomycin D in its list of authorized medicinal products.
Australia	Approximately $50

Supply Chain Risk Assessment — Actinomycin

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry, including the production of Actinomycin, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70% of APIs used in Indian pharmaceuticals are sourced from China, underscoring a significant dependency on Chinese suppliers. This reliance exposes the supply chain to risks associated with geopolitical tensions, trade disputes, and potential export restrictions.

The COVID-19 pandemic highlighted the vulnerabilities of this dependency, as disruptions in Chinese manufacturing led to shortages and price surges in essential drugs. In response, the Indian government initiated the Production Linked Incentive (PLI) scheme in October 2024 to bolster domestic production of critical APIs and KSMs, aiming to reduce import dependence by half. However, the effectiveness of these measures in achieving self-sufficiency remains to be fully realized.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates that the top five exporters account for 81.1% of Actinomycin exports from India, with EUGIA PHARMA SPECIALITIES LIMITED alone contributing 61.4%. This high supplier concentration poses a significant risk, as any operational or compliance issues within these key companies could disrupt the entire supply chain.

The PLI scheme, launched in October 2024, aims to incentivize domestic production of critical APIs and KSMs. While this initiative is a step toward reducing dependency on imports and diversifying the supplier base, its impact on mitigating single-source risks in the Actinomycin supply chain is yet to be fully assessed.

Access Complete Actinomycin Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 933 transactions across 97 markets.

Request Demo View Pricing

Frequently Asked Questions — Actinomycin Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top actinomycin exporters from India?

The leading actinomycin exporters from India are EUGIA PHARMA SPECIALITIES LIMITED, MYLAN LABORATORIES LIMITED, IKRIS PHARMA NETWORK PRIVATE LIMITED, and 10 others. EUGIA PHARMA SPECIALITIES LIMITED leads with 61.4% market share ($1.8M). The top 5 suppliers together control 81.1% of total export value.

What is the total export value of actinomycin from India?

The total export value of actinomycin from India is $2.9M, recorded across 933 shipments from 184 active exporters to 97 countries. The average shipment value is $3.1K.

Which countries import actinomycin from India?

India exports actinomycin to 97 countries. The top importing countries are UNITED STATES (73.5%), BRAZIL (8.4%), UGANDA (1.3%), ETHIOPIA (1.2%), UNITED ARAB EMIRATES (1.1%), which together account for 85.5% of total export value.

What is the HS code for actinomycin exports from India?

The primary HS code for actinomycin exports from India is 30049046. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Actinomycin

Actinomycin

Top Actinomycin Exporters from India

Top Countries Importing Actinomycin from India

Who Supplies Actinomycin to India?

Quick Facts

Related Advanced Oncology

Related Analysis

Need Details?

Actinomycin — Export Intelligence Video

Regulatory Landscape — Actinomycin

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Actinomycin

Supply Chain Risk Assessment — Actinomycin

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Actinomycin Trade Intelligence

Frequently Asked Questions — Actinomycin Exports from India

Who are the top actinomycin exporters from India?

What is the total export value of actinomycin from India?

Which countries import actinomycin from India?

What is the HS code for actinomycin exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of actinomycin exports from India?

Which ports handle actinomycin exports from India?

Why is India a leading exporter of actinomycin?

What certifications do Indian actinomycin exporters need?

How many buyers import actinomycin from India?

What is the market share of the top actinomycin exporter from India?

Analysis Methodology